CD4 and neoplasm: In another clinical trial, long peptide cancer vaccines that target predicted personal tumor neoantigens, administered alone or in combination with anti-PD-1, resulted in clinical benefits and induced polyfunctional CD4+ and CD8+ T cells, with expansion of the repertoire of neoantigen-specific T cells (132).